Who can use Datroway(DatopotamabDeruxtecan-dlnk)?

DATROWAY is approved for treating a specific type of advanced breast cancer in adults.

Indications

DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, as confirmed by IHC 0, IHC 1+, or IHC 2+/ISH- testing. Eligible patients must have previously received endocrine-based therapy and chemotherapy for their advanced disease. This approval is based on clinical trial data demonstrating efficacy in this population, providing a new treatment option after prior systemic therapies have been used.